| Market Capitalization (Millions $) |
336 |
| Shares
Outstanding (Millions) |
100 |
| Employees |
229 |
| Revenues (TTM) (Millions $) |
90 |
| Net Income (TTM) (Millions $) |
-91 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Cellectis S.A. is a French biotechnology company focused on developing innovative immunotherapies for the treatment of cancer. The company utilizes gene editing technology, specifically TALEN (Transcription Activator-Like Effector Nucleases), to modify immune cells and create personalized chimeric antigen receptor T-cell (CAR-T) therapies.
Cellectis S.A. primarily works on allogeneic CAR-T therapies, which are made from healthy donor cells rather than a patient's own cells. This approach has the potential to create off-the-shelf treatments that can be quickly administered to patients without the need for individualized cell manufacturing. The company's lead product candidate, UCART19, is being developed for the treatment of acute lymphoblastic leukemia (ALL) and is currently in clinical trials.
Cellectis S.A. also has a subsidiary called Calyxt, which focuses on developing plant-based products with improved traits using gene editing technologies. This includes agricultural crops with enhanced nutritional value, sustainability, and resistance to diseases.
Overall, Cellectis S.A. aims to revolutionize cancer treatment by harnessing the power of gene editing to create targeted immunotherapies that could potentially provide safer and more effective treatment options for patients.
Company Address: 8, rue de la Croix Jarry Paris 75013
Company Phone Number: 1 81 69 16 00 Stock Exchange / Ticker: NASDAQ CLLS
|
3% 